Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated)

American Journal of Surgery

Volumn 184, Issue 6 SUPPL. 1, 2002, Pages S19-S24

  Morris, Peter E ^a   Light, R Bruce ^b   Garber, Gary E ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BREAST FEEDING; CHRONIC KIDNEY FAILURE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DYING; HUMAN; HYPERCOAGULABILITY; IMMUNOPATHOLOGY; INTENSIVE CARE; MORBID OBESITY; PATIENT SELECTION; PREGNANCY; PRIORITY JOURNAL; SAFETY; SEPSIS; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION;

EID: 0036944377     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)01133-9     Document Type: Article

References (22)

1. Hartman D.L., Bernard G.R., Helterbrand J.D., et al. Recombinant human activated protein C (rhAPC) improved coagulation abnormalities associated with severe sepsis. [abstract] Intensive Care Med. 24:1998;S77.
2. Taylor F.B. Jr, Chang A., Esmon C.T., et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
3. Taylor F.B. Jr, Stearns-Kurosawa D.J., Kurosawa S., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 95:2000;1680-1686.
4. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
5. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 266:1962;905-909.
6. Rinder H.M., Arbini A.A., Snyder E.L. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol. 6:1999;437-441.
7. McMahan D.A., Smith D.M., Carey M.A., Zhou X.H. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 13:1998;311-316.
8. Faioni E.M., Franchi F., Krachmalnicoff A., et al. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency an inhibitor of protein C is present in uremic plasma . Thromb Haemost. 66:1991;420-425.
9. Mezzano D., Espana F., Panes O., et al. Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients relationship with systemic inflammation and haemostatic activation . Br J Haematol. 113:2001;905-910.
10. Jacobs L.G., Nusbaum N. Perioperative management and reversal of antithrombotic therapy. Clin Geriatr Med. 17:2001;189-202.
11. Choy J.B., Armstrong P.W. Anticoagulant therapy in unstable angina. Cardiol Clin. 17:1999;327-343.
12. White B., Schmidt M., Murphy C., et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappa-B (NF-κB) and tumour necrosis factor alpha (TNF-α) production in the THP-1 monocytic cell line. Br J Haematol. 110:2000;130-134.
13. Petaja J., Pesonen E., Fernandez J.A., et al. Activated protein C and inflammation in human myocardium after heart surgery. Am J Hematol. 67:2001;210-212.
14. Yoshikawa A., Kaido T., Seto S., et al. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats. J Hepatol. 33:2000;953-960.
15. Joyce D.E., Gelbert L., Ciaccia A., et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 276:2001;11199-11203.
16. Esmon C.T. Role of coagulation inhibitors in inflammation. Thromb Haemost. 86:2001;51-56.
17. Walson P.D. Patient recruitment US perspective . Pediatrics. 104:1999;619-622.
18. Hoppu K. Patient recruitment European perspective . Pediatrics. 104:1999;623-626.
19. Giroir B. Baseline disease characteristics, pharmacodynamics, and pharmacokinetics in pediatric severe sepsis patients in the open-label trial of drotrecogin alfa (activated). [abstract] Crit Care Med. 30:2001;493.
20. Xigris. [package insert]. Indianapolis, IN: Eli Lilly and Company; 2001.
21. Polderman K.H., Girbes A.R., Thijs L.G., Strack van Schijndel R.J. Accuracy and reliability of APACHE II scoring in two intensive care units. Problems and pitfalls in the use of APACHE II and suggestions for improvement. Anaesthesia. 56:2001;47-50.
22. Polderman K.H., Jorna E.M., Girbes A.R. Inter-observer variability in APACHE II scoring effect of strict guidelines and training . Intensive Care Med. 27:2001;1365-1369.